PLANNING AND EVALUATION (Core-453) ABSTRACT Overview: The University of Colorado Cancer Center's (UCCC) Planning and Evaluation (P&E) activities, under the leadership of Dan Theodorescu MD PhD, are focused on the comprehensive strategic review of the UCCC and its Research Programs, Shared Resources (SRs), Clinical Research, and associated operations to ensure the optimization of UCCC's activities and the recognition and pursuit of particular opportunities. The P&E component is conducted in a multi-faceted approach that includes the review and assessment by the External Advisory Board (EAB), several key internal advisory committees, and the Senior Leadership of the UCCC. These activities are augmented by specific ad hoc individual and group external reviewers along with key input from UCCC members through UCCC organizational structures. Following the NCI Site Visit of the UCCC in June 2011 and receipt of the detailed CCSG review, UCCC Senior Leadership and Research Program Leaders initiated a series of meetings to identify key areas for development and recruitment in addition to those strategic directions outlined in the Director's Overview. Key areas were identified as recruitment of an Associate Director for Population Sciences Research, the reconstruction of the Protocol Review and Monitoring System (PRMS) which had been disapproved and implementation of better educational opportunities and infrastructure (new clinical trial management system (CTMS)) in support of clinical investigation. The UCCC External Advisory Board (EAB) played a critical role in this strategic planning and evaluation activities through annual visits and written feedback. Accomplishments: Since 2011 such P&E activities have led to the successful accomplishments of many of the strategic directions outlined in the Director's Overview in addition to the key areas outlined above. In the next funding period, the P&E component proposes the following Specific Aims: 1) Creation of appropriate external and internal advisory bodies to ensure strategic development, expert guidance, and rigorous review of UCCC research programs and activities; and 2) Development of processes for continuous review and improvement of UCCC programs to ensure efficiency, effectiveness, and concordance with UCCC strategic initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-29
Application #
9207573
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
29
Fiscal Year
2017
Total Cost
$12,761
Indirect Cost
$4,554
Name
University of Colorado Denver
Department
Type
Domestic Higher Education
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464
Elder, Alan M; Tamburini, Beth A J; Crump, Lyndsey S et al. (2018) Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer Res 78:6473-6485

Showing the most recent 10 out of 1634 publications